Cardiomyocyte Differentiation of Rat Bone Marrow Multipotent Progenitor Cells Is Associated with Downregulation of Oct-4 Expression by Lu, Tiewei et al.
Original Article
Cardiomyocyte Differentiation of Rat Bone Marrow
Multipotent Progenitor Cells Is Associated
with Downregulation of Oct-4 Expression
Tiewei Lu, M.D.,1,2 Beatriz Pelacho, Ph.D.,3 Hong Hao, Ph.D.,2 Min Luo, M.D.,2 Jing Zhu, Ph.D.,1
Catherine M. Verfaillie, M.D.,3 Jie Tian, M.D.,1 and Zhenguo Liu, M.D., Ph.D.1,2
This study was to determine if bone marrow multipotent adult progenitor cells (MAPCs) underwent cardiac
specification and Oct-4 expression during their cardiomyocyte differentiation in vitro. MAPCs were isolated from
rat bone marrow, treated with 5-azacytidine (5-aza, 1 mM) for 24 h, and cultured in a serum-free medium for
cardiac differentiation for up to 35 days. The cells started to express early cardiac-specific genes Nkx2.5 and
GATA-4 with a significant increase in their mRNA level within 24 h after 5-aza treatment. Western blotting
analysis and immunofluorescence staining revealed that the cardiac-specific proteins connexin-43 and troponin I
were expressed in the cells 7 days after 5-aza treatment. Flow cytometry analysis demonstrated that over 37% of
the cells were positive for troponin I by 35 days of differentiation, although the cells did not display spontaneous
contraction. On the other hand, the undifferentiated MAPCs expressed a significant level of the stem-cell-specific
marker Oct-4 that was dramatically decreased in the cells shortly after the initiation of cardiomyocyte differ-
entiation as evaluated using real-time (RT)-polymerase chain reaction, Western blotting, immunofluorescence
staining, and flow cytometry. These data indicated that MAPCs were able to effectively differentiate into
cardiomyocyte-like cells after 5-aza induction in association with downregulation of Oct-4 expression.
Introduction
Cell transplantation into the damaged myocardiumhas remained a viable option for the repair and regen-
eration of myocardial injuries. Bone marrow mesenchymal
stem cells (MSCs) are one of the main sources of cell therapy
for cardiac repair and regeneration since these cells are easily
obtainable without ethical concerns, and have little (if any)
inherent immunogenicity for any adverse immune reac-
tions.1–3
Bone marrow multipotent adult progenitor cells (MAPCs)
are one of the well-defined MSCs, and have been isolated
and purified form bone marrow, skeletal muscle, and brain
in rat, mouse, and human.4,7 These cells express a high level
of the stem cell marker Oct-4, exhibit extensive expansion
capability without telomere shortening or karyotypic ab-
normalities, and are able to differentiate at the single-cell
level into functional multiple cell lineages of all three
germinal layers, including endothelial cells, osteoblasts,
smooth-muscle-like cells, skeletal myoblasts, hepatocytes,
and neurons both in vitro and in vivo.4–10 When injected into
an early mouse blastocyst, a single undifferentiated MAPC
contributes to the cell populations in most (if not all) organ
systems.9 Although transplantation of these cells into the
peri-infarction areas enhances left ventricular contractile
function after acute myocardial infarction in animal stud-
ies,10,11 there is no evidence showing that these cells differ-
entiate into cardiomyocytes. However, other MSCs have
been shown to be able to undergo cardiac specification in the
presence of 5-azacytidine (5-aza, a DNA hypomethylation
agent) or coculture with mature cardiomyocytes, although
the efficacy of MSC differentiation into cardiomyocyte has
been very inconsistent in both in vivo and in vitro studies.3
In the present study, we examined if MAPCs were able to
differentiate into cardiomyocytes in response to 5-aza in-
duction. Our data demonstrated that after 5 weeks of dif-
ferentiation, over 37% of cells exhibited the phenotypic
characteristics of cardiomyocytes with expression of cardiac-
specific genes and proteins, including Nkx2.5, GATA-4,
connexin-43, and troponin I. At the same time, Oct-4 ex-
pression was substantially downregulated in the cells at the
early phase of cardiac differentiation. These results indicated
that MAPCs were indeed able to undergo cardiac specifica-
tion in vitro when the conditions were optimal.
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Materials and Methods
Isolation and culture of MAPCs
Rat MAPCs were isolated and purified from rat bone
marrow as described previously in detail.4,7 The cells were
then cultured in expansion medium in dishes coated with
100 ng/mL fibronectin (FN; Sigma) at 378C with 5% O2, 5%
CO2, and 90% N2, and were strictly kept at a density of 100–
200 cells/cm2 to avoid cell–cell contact as described.4,7
Cardiomyocyte differentiation of MAPCs
MAPCs were plated with cell density of 67,000/cm2 in
10-cm FN-coated Petri dishes in the MAPC culture medium,
and cardiomyocyte differentiation was initiated by switching
the cells to a differentiation medium (MAPC medium
without fetal bovine serum, platelet-derived growth factor,
epidermal growth factor [EGF], and leukeamia inhibitory
factor [LIF]) in the presence of 1 mM 5-aza (Sigma). After
24 h of incubation with 5-aza, the cells were maintained for
up to 35 days at 378C with 5% O2, 5% CO2, and 90% N2, in
the differentiation medium without 5-aza with medium
change every 24–48 h. The differentiation process was closely
monitored with cell morphology and expression of the
cardiomyocyte-specific markers as described below.
Immunofluorescence staining
Undifferentiated or differentiating MAPCs were plated in
FN-coated chamber slides. The cells were collected at dif-
ferent time points of differentiation (from day 1 to 35), and
fixed with 4% paraformaldehyde (Sigma) for 30min at room
temperature. The cells were further prepared for immuno-
fluorescence staining as described previously.4,12 The dilu-
tion factor for the primary antibodies against connexin-43,
troponin I, and Oct-4 (all from Santa Cruz) was 1:200, and for
the secondary antibodies (species-specific fluorescein-
isothiocyanate-conjugated immunoglobulin G; Sigma) was
1:200. Cells exposed to the secondary antibodies only were
used as negative controls in addition to the nuclear stain
DAPI (Molecular Probes) at a dilution factor of 1:1000. The
cells were then examined with fluorescence microscopy
(Zeiss Axiovert; Carl Zeiss, Inc.).
Quantitative real-time-polymerase chain reaction
(RT-PCR) analysis
Total RNA was extracted from undifferentiated and 5-aza-
treated MAPCs at different time points of differentiation
using the RNeasy RNA isolation kit (Qiagen Inc.) as per
manufacturer’s instruction, and quantified by spectropho-
tometry at 260 nm. The mRNA was reversely transcribed
using a TaqMan Reverse Transcription Reagents Kit (Ap-
plied Biosystems) as described.8,12 The primers used for am-
plification are listed in Table 1. The mRNA levels were
normalized using GAPDH as housekeeping gene.
West blot analysis
Cell lysates were prepared from the undifferentiated and
5-aza-treated MAPCs at different time points for Western
immunoblot analysis to determine the expression levels of
cardiomyocyte-specific proteins troponin I and connexin-43,
as well as stem cell marker Oct-4. The supernatant was col-
lected for analysis after centrifugation at 14,000 g for 15min
at 48C. Protein concentration was determined by the BCA
protein assay (Pierce). A total of 20 mg protein was loaded on
10% sodium dodecyl sulfate–polyacrylamide gel, and im-
munoblotting was conducted as described previously.12,13
The dilution factor for the primary antibodies against
connexin-43, troponin I, Oct-4, and b-actin was 1:500, 1:500,
1:1000, and 1:1000, respectively, as recommended by the
manufacturers (Santa Cruz). The protein levels were deter-
mined using horseradish-peroxidase-linked secondary Abs
(1:10,000 dilution) and ECL System. All Western blot ex-
periments were repeated for at least three times.
Flow cytometry assay
Differentiation efficiency of MAPCs into cardiomyocytes
was evaluated by the percentage of cells positive for troponin
I after differentiation using flow cytometry. The Oct-4-
positive cells were also evaluated before and after the dif-
ferentiation using flow cytometry. Undifferentiated MAPCs
and the cells at week 5 of differentiation were harvested,
washed, and suspended in ice-cold phosphate-buffered sa-
line with the cell density of *1–5106 cells/mL. The prep-
arations were then incubated with the primary antibodies
against Oct-4 and troponin I at 48C for 30min, followed by
exposure to the fluorescein-isothiocyanate-conjugated sec-
ondary antibodies for 20min. The cells were readily to be
fixed with 4% paraformaldehyde for flow cytometry analysis
using FACS Calibur (Becton-Dickinson).
Statistical analysis
Data were presented as mean standard deviation for all
experiments, and analyzed using one-way analysis of vari-
ance (SPSS 12.0 software). A p 0.05 was considered to be
statistically significant.
Results
Morphological change of MAPCs during differentiation
Undifferentiated MAPCs characteristically displayed
multiple morphologies, including rod-like and spindle-
Table 1. Primer Sequences Used for RT-Polymerase Chain Reaction
Gene Forward Reverse
Nkx2.5 GATGCCACAGGGCAATTC TCTCCTAAAGGTGGGAGTCG
GATA-4 TCTGAATAAATCTAAGACACCAGCA GTTGCTGGAGGCACCACT
Oct-4 CTGTAACCGGCGCCAGAA TGCATGGGAGAGCCCAGA
GAPDH CAGTGCCAGCCTCGTCTCAT AGGGGCCATCCACAGTCTTC
RT, real time.
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shaped appearance. By day 14 of differentiation, the cells
started to exhibit myotube-like structures that were typically
observed in cardiomyocytes (data not shown). However, no
spontaneous contraction was present in the cells in the cul-
ture system for up to 35 days.
Transcriptional expression of cardiomyocyte-specific
markers during differentiation
The levels of transcriptional expression of the cardiac-
specific genes Nkx2.5 and GATA-4 were determined by
quantitative RT-PCR as reflected by their mRNA levels in the
cells during differentiation. The mRNA level for Nkx2.5 was
markedly increased in the cells by over six times as com-
pared to undifferentiated cells (n¼ 4, p< 0.05) within 24 h
after 5-aza induction (Fig. 1). The mRNA level was further
increased in the cells by >10 times over control (undiffer-
entiated cells) (n¼ 4, p< 0.01) at day 3 of differentiation. Si-
milarly, enhanced expression of GATA-4 was also observed
in the differentiating cells as early as day 1 after 5-aza
treatment with significant increase in its mRNA level by
more than two times over the undifferentiated MAPCs
(n¼ 4, p< 0.05). Transcriptional expression of GATA-4 was
further increased as reflected by more than four times in-
crease in its mRNA level over control (n¼ 4, p< 0.01) at day
3 of differentiation. In contrast, expression of the stem-cell-
specific marker Oct-4 was dramatically decreased in the
differentiating cells with close to 90% reduction in its mRNA
level during differentiation (Fig. 3A).
Protein expression of cardiomyocyte-specific
markers during differentiation
Expression of cardiomyocyte-specific proteins connexin-43
and troponin I was evaluated using Western blot analysis
and fluorescence immunohistochemistry. As expected, a
significant amount of connexin-43 protein was observed in
the cells at day 7 of differentiation (Fig. 2A). The protein level
remained high in the cells during differentiation. Interest-
ingly, a detectable level of troponin I protein started to occur
in the cells by day 7 of cardiac differentiation, increased
gradually to its maximal level by day 21 during differentia-
tion, and remained at high level thereafter (Fig. 2B). The
presence of these proteins (connexin-43 and troponin I) and
their intracellular distributions were also demonstrated
using fluorescence immunohistochemistry (Fig. 2C).
As expected, a significant amount of Oct-4 protein was
observed in undifferentiated MAPCs. However, the Oct-4
protein content started to decrease significantly at day 3 of
differentiation, reached its lowest level at day 14, and stayed
at undetectable level thereafter as determined using Western
blotting (Fig. 3B). The profile of Oct-4 protein expression in
the cells during differentiation was confirmed by fluores-
cence immunohistochemistry (Fig. 3C). Flow cytometry
analysis also demonstrated that the majority (over 75%) of
the undifferentiated MAPCs were positive for Oct-4, and
became negative for Oct-4 after 35 days of differentiation
(Fig. 4A).
Efficiency of cardiomyocyte differentiation
by flow cytometry
Flow cytometry was used to identify the cells positive for
cardiomyocyte-specific maker troponin I after differentiation.
By day 35 of differentiation, the cells positive for troponin I
were 37.4% (Fig. 4B), indicating that a significant portion of
MAPCs was phenotypically cardiomyocyte-like cells under
the present experimental conditions. These data also sug-
gested that MAPCs were more efficient on differentiating
into cardiomyocyte-like cells than other MSCs under similar
conditions in vitro.3
Discussion
In the present study, we systematically demonstrated that
MAPCs were able to differentiate into cardiomyocyte-like
FIG. 1. Transcriptional expression of early cardiomyocyte-specific genes NKx2.5 and GATA-4 was determined by mea-
suring their mRNA levels. Their expression profiles were very similar in the cells during differentiation. The mRNA levels for
both Nkx2.5 (A) and GATA-4 (B) were significantly increased in the cells as compared to the undifferentiated control cells
within 24 h after 5-azacytidine induction, and were further increased at day 3 of differentiation, and remained at high levels
until day 7, followed by a rapid decline and stayed at stable and yet elevated levels for the remaining course of differentiation
up to 35 days. *p< 0.05 versus undifferentiated MAPCs; **p< 0.01 versus undifferentiated MAPCs (n¼ 4). MAPCs, multi-
potent adult progenitor cells.
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cells with 5-aza induction in vitro. The cells exhibited a dra-
matically enhanced transcriptional expression of the early
cardiomyocyte-specific genes Nkx2.5 and GATA-4 as re-
flected by increased mRNA levels, and expressed significant
levels of cardiomyocyte-specific proteins troponin I and
connexin-43 during the course of differentiation. At the same
time, expression of the stem-cell-specific marker Oct-4 in the
cells was dramatically downregulated shortly after the ini-
tiation of cardiomyocyte differentiation.
5-Aza is a DNA methylation inhibitor,14 and has been
used to induce cardiac differentiation of both embryonic
stem cells and MSCs.15–17 However, the efficacy of MSC
differentiation into cardiomyocyte has been very inconsistent
in both in vivo and in vitro studies.3 Some study reports that
only a very small fraction (*0.07%) of human bone marrow
MSCs could generate cardiomyocyte-like cells in vitro after
treatment with 5-aza, while some investigators show that
about 20% of MSCs exhibit cardiomyocyte phenotype after
differentiation.3,15,16,18,19 The reasons for the large outcome
variability for 5-aza-induced cardiac differentiation of MSCs
are unknown. It may be ultimately related to the population
and quality of the cells used and/or experimental conditions
that have not been standardized. In some cases, MSCs may
be a mixture of heterogeneous cells with different pheno-
types. It is also documented that not all the MSCs have
multipotent capability of differentiating into multiple cell
lineages.20 Therefore, the experimental outcomes on cardiac
differentiation of MSCs could be largely determined by the
cell population. Indeed, a recent study shows that a single
clonally purified nonhematopoietic MSC subpopulation from
human bone marrow has much higher percentage of cells
that express cardiomyocyte markers both in vitro and
FIG. 2. Expression of connexin-43 and troponin I was
evaluated using Western blotting analysis and fluorescence
immunohistochemistry during cardiac differentiation of
MAPCs. A significant amount of connexin-43 was observed in
the cells by day 7 of cardiac differentiation and thereafter (A).
Similarly, troponin I started to become detectable in the cells
by day 7 of differentiation. The protein level was increased
gradually in the cells and reached its maximum by day 21 of
differentiation, and remained at high level thereafter (B). A
representative Western blotting for connexin-43 and troponin
I was shown in the lower part of panels (A) and (B), respec-
tively. Relative expression of the proteins in the cells from
four independent experiments was summarized in the upper
part of panels (A) and (B), respectively. The presence of
connexin-43 and troponin I and their intracellular distribu-
tions were also demonstrated using fluorescence immuno-
histochemistry (C). *p< 0.05 versus undifferentiated MAPCs;
**p< 0.01 versus undifferentiated MAPCs (n¼ 4). Scale bar:
20mm. a, no fluorescence staining for connexin-43 in undif-
ferentiated MAPCs; b, by day 35 of differentiation, the cells
stained positive for connexin-43; c, no fluorescence staining
for troponin I in undifferentiated MAPCs; and d, by day 35 of
differentiation, the cells stained positive for troponin I.
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in vivo, and better preserved cardiac function with less scar
formation and smaller infarct size as compared with un-
purified MSCs or bone marrow mononuclear cells or
peripheral blood mononuclear cells.21 In addition, the 5-aza
concentrations also vary in different studies. The optimal
5-aza concentration is reported to be 10mM for cardiomyo-
genic differentiation of MSCs in vitro.22 We used different
5-aza concentrations (from 0.5 to 10mM), and observed that a
significant cell death occurred when MAPCs were incubated
with 5-aza at the concentration of 5mM or above (data not
shown). Therefore, the cells were treated with 1mM 5-aza to
initiate cardiac specification in our study. Under the present
experimental conditions, over 37% of the cells were positive
for troponin I after 35 days of differentiation, suggesting that
MAPCs might be an excellent source of cells for experimental
cardiac-cell-based therapies. Further studies are needed to
FIG. 3. Oct-4 expression was determined using real-time
(RT)-polymerase chain reaction, Western blotting, and im-
munofluorescence staining during cardiomyocyte differenti-
ation of MAPCs. Oct-4 was expressed abundantly in the
undifferentiated MAPCs at both transcriptional and transla-
tional levels as reflected by its mRNA (A) and protein levels
(B). Its expression was substantially decreased in the cells at
the early phase of cardiac differentiation. By day 14 of dif-
ferentiation, no detectable Oct-4 protein was expressed in the
cells as analyzed using Western blotting (B). Fluorescence
immunohistochemistry also showed that high level of Oct-4
protein in the undifferentiated MAPCs was no longer present
in the cells after 35 days of cardiomyocyte differentiation (C).
*p< 0.05 vs undifferentiated MAPCs.
FIG. 4. Flow cytometry analysis of
Oct-4 and troponin I expression during
cardiac differentiation of MAPCs. The
expression profiles of Oct-4 and tropo-
nin I were analyzed using flow cytom-
etry in the cells before and after their
differentiation. There was a clear shift of
cell populations that expressed Oct-4
and troponin I during the cardiomyo-
cyte differentiation. The Oct-4-positive
cell population diminished after 5 weeks
of differentiation (A), whereas the tro-
ponin-I-negative cells became troponin-
I-expressing cells at the same time (B).
Color images available online at
www.liebertonline.com/ten.
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investigate the in vivo cardiac commitment of MAPCs and
their participation in cardiac repair and/or regeneration.
However, the optimal conditions for the in vivo studies need to
be defined. Future experiments are also warranted to deter-
mine if similar efficacy of cardiomyocyte differentiation could
be achieved using human MAPCs both in vitro and in vivo.
Stem cell differentiation is a complex and tightly con-
trolled process that involves many transcripts and pro-
teins.5 Oct-4 is a transcription factor, and is expressed at
high levels in the pluripotent cells of preimplantation em-
bryos and most germ line cells. Oct-4 expression in mouse
embryonic stem cells is widely considered as a hallmark of
cell pluripotency and critical to the regulation of embryonic
differentiation.23,24 Adequate Oct-4 expression alone is
sufficient to generate pluripotent stem cells from adult
mouse neural stem cells.25,26 Oct-4 is expressed abundantly
in MAPCs.8,13 Its expression is dramatically decreased in
MAPCs at the early phase of their endothelial differentia-
tion.27 Interestingly, similar results were obtained during
cardiac differentiation in the present study. A rapid
downregulation of Oct-4 expression in MAPCs may be a
key step to the commitment of MAPCs to cardiomyocytes
or endothelial cells. To our knowledge, this was the first
time to demonstrate that cardiac differentiation of bone
marrow stem cells was associated with downregulation of
Oct-4 expression. Further studies are needed to define the
role of Oct-4 in this process.
One of the characteristics of cardiomyocytes is their
spontaneous contraction and unique ionic currents and
membrane potential. It has been reported that spontaneous
beating clusters of cells are present in the cardiomyocytes
generated from MSCs in vitro with L-type Ca(2þ) currents
and rectifying K(þ) currents of rapid or slow activation
kinetics.18,28 However, in the present study, no spontaneous
contraction was observed in the cells differentiated from
MAPCs. The reason for the apparent difference in the
spontaneous contraction is unknown. One very likely pos-
sibility is the difference in cell preparations used in these
experiments that is supported by a recent observation that
cardiomyocytes derived from an MSC population in mice
bone marrow do not display any spontaneous contraction,
nor generate action potentials or ionic currents typical of
cardiomyocytes.29 However, further investigation is war-
ranted to evaluate the functional status of these cells
although the proteins for the propagation of electric activity
in the ventricles (connexin-43, a cardiac-specific gap-junction
protein),30 and for contraction (troponin I) were present in
the differentiated cells. We did not evaluate the ionic cur-
rents and membrane potential or action potential in the cells
since they did not display spontaneous contraction.
In conclusion, the present study demonstrated that rat
MAPCs successfully differentiated into cardiomyocyte-like
cells after 5-aza induction with high efficacy in vitro. Cardiac
differentiation of MAPCs was associated with down-
regulation of Oct-4 expression. These data suggested that
MAPCs could potentially serve as an important source for
experimental cell-based therapies for cardiac repair and
regeneration.
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